EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacogenomics for neurodegenerative disorders - a focused review

S Rehan Ahmad, Md Zeyaullah, Mohammad Suhail Khan, Abdullah M AlShahrani, Abdelrhman A Galaleldin Altijani, Haroon Ali, Adam Dawria, Ali Mohieldin, Mohammad Shane Alam, Awad Osman Abdalla Mohamed

Frontiers in Pharmacology · 20.12.2024 · 15

DOI: 10.3389/fphar.2024.1478964 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.12.2024. Verfasst von S Rehan Ahmad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hiralal Mazumdar Memorial College for Women, West Bengal State University, Kolkata, India. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research, King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are characterized by the progressive degeneration of neuronal structure and function, leading to severe cognitive and motor impairments. These conditions present significant challenges to healthcare systems, and traditional treatments often fail to account for genetic variability among patients, resulting in inconsistent therapeutic outcomes. Pharmacogenomics aims to tailor medical treatments based on an individual’s genetic profile, thereby improving therapeutic efficacy and reducing adverse effects. This focused review explores the genetic factors influencing drug responses in neurodegenerative diseases and the potential of pharmacogenomics to revolutionize their treatment. Key genetic markers, such as the APOE ε4 allele in AD and the CYP2D6 polymorphisms in PD, are highlighted for their roles in modulating drug efficacy. Additionally, advancements in pharmacogenomic tools, including genome-wide association studies (GWAS), next-generation sequencing (NGS), and CRISPR-Cas9, are discussed for their contributions to personalized medicine. The application of pharmacogenomics in clinical practice and its prospects, including ethical and data integration challenges, are also examined.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseHuntington’s diseaseParkinson’s diseaseamyotrophic lateral sclerosisgenome-wide association studiesneurodegenerative disordersnext-generation sequencingpharmacogenomics

Autor:innen und Institutionen

  • Hiralal Mazumdar Memorial College for Women, West Bengal State University, Kolkata, India.
  • Department of Basic Medical Science, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University (KKU), Abha, Saudi Arabia.
  • Department of Public Health, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University (KKU), Abha, Saudi Arabia.
  • Department of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia.
  • Department of Anaesthesia Technology, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University (KKU), Abha, Saudi Arabia.

Förderung

  • Deanship of Scientific Research, King Khalid University

Zitieren

APA

Ahmad, S. R., Zeyaullah, M., Khan, M. S., AlShahrani, A. M., Altijani, A. A. G., Ali, H., Dawria, A., Mohieldin, A., Alam, M. S., & Mohamed, A. O. A. (2024). Pharmacogenomics for neurodegenerative disorders - a focused review. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1478964

Vancouver

Ahmad SR, Zeyaullah M, Khan MS, AlShahrani AM, Altijani AAG, Ali H, et al. Pharmacogenomics for neurodegenerative disorders - a focused review. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1478964

BibTeX
@article{Ahmad2024,
  author = {Ahmad, S Rehan and Zeyaullah, Md and Khan, Mohammad Suhail and AlShahrani, Abdullah M and Altijani, Abdelrhman A Galaleldin and Ali, Haroon and Dawria, Adam and Mohieldin, Ali and Alam, Mohammad Shane and Mohamed, Awad Osman Abdalla},
  title = {Pharmacogenomics for neurodegenerative disorders - a focused review},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1478964}
}
Kostenlos starten →